Wound Care Scar Management: Prevention and Treatment

Wound Care Scar Management Starts Before the Wound Closes

Scar management in wound care is not an afterthought that begins when the wound finally epithelializes. The interventions that most influence scar quality happen during the proliferative and remodeling phases of wound healing, often weeks or months before the patient asks about their scar. By the time a patient presents with a mature, symptomatic scar, the window for the most effective interventions has already narrowed.

Every wound that extends beyond the epidermis will produce a scar. The clinical question is not whether a scar will form, but whether the scar will be flat, pliable, and asymptomatic, or raised, contracted, pruritic, and functionally limiting. The answer depends on wound management during healing, patient risk factors, and early post-closure intervention.

For burns, which carry the highest scarring risk, see our Outpatient Burn Management Guide.

Scar Types: Clinical Classification

Understanding scar pathology drives treatment selection. Not all abnormal scars respond to the same interventions.

Hypertrophic Scars

Hypertrophic scars are raised, firm, and erythematous, but they stay within the boundaries of the original wound. They typically develop within four to eight weeks of wound closure and may partially regress over 12-24 months. Hypertrophic scars are caused by excessive collagen deposition during the proliferative phase, driven by prolonged inflammation, wound tension, and delayed epithelialization.

High-tension wound locations such as the sternum, shoulders, and joints across flexion surfaces are particularly prone to hypertrophic scarring. Wounds that took longer than two to three weeks to epithelialize have significantly higher rates of hypertrophic scar formation.

Keloid Scars

Keloids extend beyond the original wound boundaries, invading surrounding normal tissue. Unlike hypertrophic scars, keloids do not spontaneously regress and have a high recurrence rate after excision (50-80% without adjunct therapy). Keloid formation has a strong genetic component, with higher prevalence in patients of African, Asian, and Hispanic descent.

Keloids can develop months or even years after wound closure. Common sites include the earlobes, deltoid region, upper back, and anterior chest. The pathophysiology involves dysregulated collagen synthesis with inadequate collagen breakdown, resulting in progressive tissue accumulation.

Atrophic Scars

Atrophic scars are depressed below the surrounding skin surface, resulting from inadequate collagen deposition during healing. They are most commonly associated with acne, varicella, and tissue loss injuries where the wound bed lacked sufficient dermal support for normal remodeling. Atrophic scars in wound care settings typically result from full-thickness tissue loss wounds that healed by secondary intention with insufficient granulation tissue volume.

Prevention Strategies During Wound Healing

Optimize the Healing Environment

Wounds that heal faster scar less. Maintaining a moist wound environment, controlling bacterial bioburden, ensuring adequate perfusion, and managing underlying conditions (diabetes, malnutrition, immunosuppression) all contribute to faster epithelialization and reduced scar severity.

Debridement of necrotic tissue and management of excessive exudate prevent prolonged inflammation, which is the primary driver of excessive scar formation. Every additional day of wound inflammation increases the risk of pathological scarring.

Minimize Wound Tension

Tension across the wound edges during healing stimulates fibroblast activity and collagen overproduction. Use tension-reducing closure techniques whenever possible. For surgical wounds, layered closure that distributes tension across tissue planes reduces surface tension on the epidermis. Paper wound closure strips applied perpendicular to the wound after suture removal maintain reduced tension during the vulnerable early remodeling phase.

Protect From UV Exposure

Ultraviolet radiation stimulates melanocyte activity in healing tissue, leading to permanent hyperpigmentation in scars. Instruct patients to protect healing wounds and new scars from sun exposure for a minimum of 12 months using clothing coverage or broad-spectrum SPF 30+ sunscreen. This is one of the simplest and most frequently neglected scar prevention measures.

Treatment Modalities for Established Scars

Silicone-Based Therapy

Silicone gel sheeting and silicone gel are the first-line treatment for hypertrophic and keloid scars, supported by the strongest evidence base of any scar treatment modality. The mechanism involves hydration of the stratum corneum and modulation of fibroblast activity through the silicone-skin interface.

Apply silicone gel sheets for a minimum of 12 hours per day (ideally 23 hours) for at least 8-12 weeks. Begin application as soon as the wound is fully epithelialized and can tolerate the adhesive without skin breakdown. For areas where sheeting is impractical (face, hands, mobile joints), topical silicone gel applied twice daily provides a practical alternative with similar evidence support.

Pressure Therapy

Pressure garments delivering 15-40 mmHg of sustained pressure reduce hypertrophic scar formation, particularly in burn scars. The mechanism involves collagen fiber realignment, reduced blood flow to the scar tissue, and accelerated scar maturation. Pressure therapy is most effective when initiated early (within weeks of wound closure) and maintained for 12-18 months.

Custom-fitted pressure garments are preferred over off-the-shelf compression for consistent pressure delivery. Patient compliance is the primary barrier because garments are uncomfortable, require daily wear for months, and need replacement as they lose elasticity.

Intralesional Corticosteroid Injection

Triamcinolone acetonide (10-40 mg/mL) injected directly into hypertrophic or keloid scar tissue reduces collagen synthesis and promotes collagen degradation. Inject into the body of the scar, not the surrounding tissue. Treatments are typically repeated every 4-6 weeks for 3-6 sessions. Common side effects include dermal atrophy, hypopigmentation, and telangiectasia at the injection site.

For keloids, corticosteroid injection is often combined with excision to reduce the 50-80% recurrence rate of excision alone. Post-excision injection series beginning within days of surgery is the current standard of care for keloid management.

Patient Expectations and Education

Managing patient expectations about scarring outcomes is a clinical responsibility. Patients often expect scars to be invisible after treatment, which is unrealistic. Set clear expectations at the time of wound closure.

Communicate three realities: scars continue to mature and improve for 12-18 months after wound closure, and premature assessment of final scar quality leads to unnecessary interventions; scar treatment reduces severity but does not eliminate scars; and individual healing biology, genetics, and wound location are stronger predictors of scar outcome than any single treatment modality.

For comprehensive patient education approaches across wound care topics, see our Patient Education Materials Guide.

Key Takeaways

Scar prevention starts during wound healing, not after closure -- optimizing the healing environment, minimizing wound tension, and reducing inflammation all decrease pathological scarring risk.
Silicone gel sheeting (12+ hours daily for 8-12 weeks) is the first-line evidence-based treatment for both hypertrophic and keloid scars.
Keloids extend beyond wound boundaries, do not spontaneously regress, and recur in 50-80% of cases after excision alone -- adjunct therapy (corticosteroid injection, pressure, radiation) is mandatory.
UV protection of new scars for at least 12 months prevents permanent hyperpigmentation and is one of the simplest yet most neglected interventions.
Set patient expectations early because scar maturation takes 12-18 months and no treatment eliminates scars entirely.